6 results on '"Garufi Carlo"'
Search Results
2. Prediction of overall survival through circadian rest-activity monitoring during chemotherapy for metastatic colorectal cancer
- Author
-
Innominato, Pasquale F., Giacchetti, Sylvie, Bjarnason, Georg A., Focan, Christian, Garufi, Carlo, Coudert, Bruno, Iacobelli, Stefano, Tampellini, Marco, Durando, Xavier, Mormont, Marie-Christine, Waterhouse, Jim, and Lévi, Francis A.
- Published
- 2012
- Full Text
- View/download PDF
3. Efficacy and safety of chronomodulated irinotecan, oxaliplatin, 5-fluorouracil and leucovorin combination as first- or secondline treatment against metastatic colorectal cancer: Results from the International EORTC 05011 Trial.
- Author
-
Innominato, Pasquale F., Karaboué, Abdoulaye, Focan, Christian, Chollet, Philippe, Giacchetti, Sylvie, Bouchahda, Mohamed, Ulusakarya, Ayhan, Torsello, Angela, Adam, René, Lévi, Francis A., and Garufi, Carlo
- Subjects
COLORECTAL cancer ,IRINOTECAN ,METASTASIS ,DRUG efficacy ,OXALIPLATIN - Abstract
The triplet combination of irinotecan, oxaliplatin and fluorouracil is an active frontline regimen in metastatic colorectal cancer, but scarce data exist on its use as salvage treatment. We aimed at assessing its safety and efficacy profiles with its circadianbased administration (chronoIFLO5) as either first- or second-line treatment, within the time-finding EORTC 05011 trial. Five-day chronoIFLO5 was administered every 3 weeks in patients with PS 0, 1 or 2. It consisted of chronomodulated irinotecan (180 mg/sqm), oxaliplatin (80 mg/sqm) and fluorouracil-leucovorin (2800 and 1200 mg/sqm, respectively). For our study, toxicity and antitumour activity were evaluated separately in first- and second-line settings. Primary endpoints included Grade 3-4 toxicity rates, best objective response rate (ORR), progression-free survival (PFS) and overall survival (OS). One-hundred forty-nine and 44 patients were treated in first-line and second-line settings, respectively, with a total of 1138 cycles with median relative dose intensities of about 90%. Demographics were comparable in the two groups. Thirty-six (24.7%) and 10 (22.2%) patients experienced at least one episode of severe toxicity in first line and second line, respectively. Frontline chronoIFLO5 yielded an ORR of 62.3% [95% CI: 54.2-70.4] and resulted in median PFS and OS of 8.7 months [7.5-9.9] and 19.9 months [15.4-24.5]. Corresponding figures in second line were 37.5% [22.5-52.5], 6.7 months [4.8-8.9] and 16.3 months [11.8-20.8]. International and prospective evaluation revealed the favourable safety and efficacy profiles of chronoIFLO5, both as frontline and as salvage treatment against metastatic colorectal cancer. In particular, encouraging activity in second line was observed, with limited haematological toxicity [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
4. Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti‐HER2 agents in the real world setting
- Author
-
Pizzuti, Laura, primary, Krasniqi, Eriseld, additional, Barchiesi, Giacomo, additional, Della Giulia, Marina, additional, Izzo, Fiorentino, additional, Sanguineti, Giuseppe, additional, Marchetti, Paolo, additional, Mazzotta, Marco, additional, Giusti, Raffaele, additional, Botticelli, Andrea, additional, Gamucci, Teresa, additional, Natoli, Clara, additional, Grassadonia, Antonino, additional, Tinari, Nicola, additional, Iezzi, Laura, additional, Tomao, Silverio, additional, Tomao, Federica, additional, Tonini, Giuseppe, additional, Santini, Daniele, additional, Astone, Antonio, additional, Michelotti, Andrea, additional, De Angelis, Claudia, additional, Mentuccia, Lucia, additional, Vaccaro, Angela, additional, Magnolfi, Emanuela, additional, Gelibter, Alain, additional, Magri, Valentina, additional, Cortesi, Enrico, additional, D'Onofrio, Loretta, additional, Cassano, Alessandra, additional, Rossi, Ernesto, additional, Cazzaniga, Marina, additional, Moscetti, Luca, additional, Omarini, Claudia, additional, Piacentini, Federico, additional, Fabbri, Maria A., additional, Scinto, Angelo F., additional, Corsi, Domenico, additional, Carbognin, Luisa, additional, Bria, Emilio, additional, La Verde, Nicla, additional, Samaritani, Riccardo, additional, Garufi, Carlo, additional, Barni, Sandro, additional, Mirabelli, Rosanna, additional, Sarmiento, Roberta, additional, Veltri, Enzo M., additional, D'Auria, Giuliana, additional, Paris, Ida, additional, Giotta, Francesco, additional, Lorusso, Vito, additional, Cardillo, Franca, additional, Landucci, Elisabetta, additional, Mauri, Maria, additional, Ficorella, Corrado, additional, Roselli, Mario, additional, Adamo, Vincenzo, additional, Ricciardi, Giuseppina R.R., additional, Russo, Antonio, additional, Berardi, Rossana, additional, Pistelli, Mirco, additional, Fiorio, Elena, additional, Cannita, Katia, additional, Sini, Valentina, additional, D'Ostilio, Nicola, additional, Foglietta, Jennifer, additional, Greco, Filippo, additional, Zamagni, Claudio, additional, Garrone, Ornella, additional, Di Cocco, Barbara, additional, Baldini, Editta, additional, Livi, Lorenzo, additional, Desideri, Isacco, additional, Meattini, Icro, additional, Sarobba, Giuseppina, additional, Del Medico, Pietro, additional, De Tursi, Michele, additional, Generali, Daniele, additional, De Maria, Ruggero, additional, Risi, Emanuela, additional, Ciliberto, Gennaro, additional, Sperduti, Isabella, additional, Villa, Alice, additional, Barba, Maddalena, additional, Di Leo, Angelo, additional, and Vici, Patrizia, additional
- Published
- 2019
- Full Text
- View/download PDF
5. Efficacy and safety of chronomodulated irinotecan, oxaliplatin, 5-fluorouracil and leucovorin combination as first- or second-line treatment against metastatic colorectal cancer: Results from the International EORTC 05011 Trial.
- Author
-
Innominato PF, Karaboué A, Focan C, Chollet P, Giacchetti S, Bouchahda M, Ulusakarya A, Torsello A, Adam R, Lévi FA, and Garufi C
- Abstract
The triplet combination of irinotecan, oxaliplatin and fluorouracil is an active frontline regimen in metastatic colorectal cancer, but scarce data exist on its use as salvage treatment. We aimed at assessing its safety and efficacy profiles with its circadian-based administration (chronoIFLO5) as either first- or second-line treatment, within the time-finding EORTC 05011 trial. Five-day chronoIFLO5 was administered every 3 weeks in patients with PS 0, 1 or 2. It consisted of chronomodulated irinotecan (180 mg/sqm), oxaliplatin (80 mg/sqm) and fluorouracil-leucovorin (2800 and 1200 mg/sqm, respectively). For our study, toxicity and antitumour activity were evaluated separately in first- and second-line settings. Primary endpoints included Grade 3-4 toxicity rates, best objective response rate (ORR), progression-free survival (PFS) and overall survival (OS). One-hundred forty-nine and 44 patients were treated in first-line and second-line settings, respectively, with a total of 1138 cycles with median relative dose intensities of about 90%. Demographics were comparable in the two groups. Thirty-six (24.7%) and 10 (22.2%) patients experienced at least one episode of severe toxicity in first line and second line, respectively. Frontline chronoIFLO5 yielded an ORR of 62.3% [95% CI: 54.2-70.4] and resulted in median PFS and OS of 8.7 months [7.5-9.9] and 19.9 months [15.4-24.5]. Corresponding figures in second line were 37.5% [22.5-52.5], 6.7 months [4.8-8.9] and 16.3 months [11.8-20.8]. International and prospective evaluation revealed the favourable safety and efficacy profiles of chronoIFLO5, both as frontline and as salvage treatment against metastatic colorectal cancer. In particular, encouraging activity in second line was observed, with limited haematological toxicity., (© 2020 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.)
- Published
- 2021
- Full Text
- View/download PDF
6. Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting.
- Author
-
Pizzuti L, Krasniqi E, Barchiesi G, Della Giulia M, Izzo F, Sanguineti G, Marchetti P, Mazzotta M, Giusti R, Botticelli A, Gamucci T, Natoli C, Grassadonia A, Tinari N, Iezzi L, Tomao S, Tomao F, Tonini G, Santini D, Astone A, Michelotti A, De Angelis C, Mentuccia L, Vaccaro A, Magnolfi E, Gelibter A, Magri V, Cortesi E, D'Onofrio L, Cassano A, Rossi E, Cazzaniga M, Moscetti L, Omarini C, Piacentini F, Fabbri MA, Scinto AF, Corsi D, Carbognin L, Bria E, La Verde N, Samaritani R, Garufi C, Barni S, Mirabelli R, Sarmiento R, Veltri EM, D'Auria G, Paris I, Giotta F, Lorusso V, Cardillo F, Landucci E, Mauri M, Ficorella C, Roselli M, Adamo V, Ricciardi GRR, Russo A, Berardi R, Pistelli M, Fiorio E, Cannita K, Sini V, D'Ostilio N, Foglietta J, Greco F, Zamagni C, Garrone O, Di Cocco B, Baldini E, Livi L, Desideri I, Meattini I, Sarobba G, Del Medico P, De Tursi M, Generali D, De Maria R, Risi E, Ciliberto G, Sperduti I, Villa A, Barba M, Di Leo A, and Vici P
- Subjects
- Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols adverse effects, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Biomarkers, Tumor, Breast Neoplasms drug therapy, Breast Neoplasms mortality, Female, Humans, Immunohistochemistry, Middle Aged, Molecular Targeted Therapy, Neoplasm Metastasis, Neoplasm Staging, Prognosis, Receptor, ErbB-2 metabolism, Receptors, Estrogen metabolism, Receptors, Progesterone metabolism, Breast Neoplasms diagnosis, Breast Neoplasms genetics, Gene Expression Regulation, Neoplastic, Receptor, ErbB-2 genetics, Receptors, Estrogen genetics, Receptors, Progesterone genetics
- Abstract
We analyzed data from 738 HER2-positive metastatic breast cancer (mbc) patients treated with pertuzumab-based regimens and/or T-DM1 at 45 Italian centers. Outcomes were explored in relation to tumor subtype assessed by immunohistochemistry (IHC). The median progression-free survival at first-line (mPFS1) was 12 months. Pertuzumab as first-line conferred longer mPFS1 compared to other first-line treatments (16 vs. 9 months, p = 0.0001), regardless of IHC subtype. Median PFS in second-line (mPFS2) was 7 months, with no difference by IHC subtype, but it was more favorable with T-DM1 compared to other agents (7 vs. 6 months, p = 0.03). There was no PFS2 gain in patients with tumors expressing both hormonal receptors (HRs; p = 0.17), while a trend emerged for tumors with one HR (p = 0.05). Conversely, PFS2 gain was significant in HRs-negative tumors (p = 0.04). Median overall survival (mOS) was 74 months, with no significant differences by IHC subtypes. Survival rates at 2 and 3 years in patients treated with T-DM1 in second-line after pertuzumab were significantly lower compared to pertuzumab-naïve patients (p = 0.01). When analyzed by IHC subtype, the outcome was confirmed if both HRs or no HRs were expressed (p = 0.02 and p = 0.006, respectively). Our results confirm that HRs expression impacts the clinical behavior and novel treatment-related outcomes of HER2-positive tumors when treatment sequences are considered. Moreover, multivariate analysis showed that HRs expression had no effect on PFS and OS. Further studies are warranted to confirm our findings and clarify the interplay between HER2 and estrogen receptor pathways in HER2-positive (mbc) patients., (© 2019 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.)
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.